Built to order: molecular tinkertoys from the [Re(6)(mu(3)-Se)(8)](2+) clusters.

Ligand substitution of [Re(6)(mu(3)-Se)(8)(PEt(3))(5)(CH(3)CN)](SbF(6))(2) (1) with pyridyl-based ligands, 2,4,6-tri-4-pyridyl-1,3,5-triazine (L1) and 5,10,15,20-tetra(4-pyridyl)-21H,23H-porphine (L2), produced respectively the star-shaped tricluster (T1) and tetracluster (T2) arrays, wherein three (T1) and four (T2) units of the [Re(6)(mu(3)-Se)(8)](2+) core-containing clusters are interconnected by the corresponding bridging ligands. These novel supramolecular assemblies were characterized by a combination of NMR ((1)H and (31)P) spectroscopy, ESI-MS, and microanalysis. The molecular and solid-state structures of T1 have also been established by single-crystal X-ray diffraction.

Halide-templated assembly of polynuclear lanthanide-hydroxo complexes.

A series of pentadecanuclear lanthanide-hydroxo complexes possessing a common core of the formula [Ln(15)(mu(3)-OH)(20)(mu(5)-X)](24+)(1, Ln = Eu, X = Cl(-); 2, Ln = Nd, X = Cl(-); 3, Ln = Gd, X = Cl(-); 4, Ln = Pr, X = Br(-); 5, Ln = Eu, X = Br(-)) were prepared by L-tyrosine-controlled hydrolysis of corresponding lanthanide perchlorates in the presence of added Cl(-) or Br(-). The cationic cluster core comprises five vertex-sharing cubane-like [Ln(4)(mu(3)-OH)(4)](8+) units centered on the halide template. In the case of templating I(-), dodecanuclear complexes were isolated instead.

A triboluminescent europium(III) complex.

The crystal structure of (4,4'-dimethyl-2,2'-bipyridyl)tris[3,3,3-trifluoro-1-(2-thenoyl)propan-2-onato]europium(III), or more commonly (4,4'-dimethyl-2,2'-bipyridyl)tris(2-thenoyltrifluoroacetonato)europium(III), [Eu(C8H4F3O2S)3(C12H12N2)], has been determined. Crystals of the complex emit vivid red light when scratched or fractured. This triboluminescent activity seems to correlate with the non-centrosymmetric crystal structure and disorder of the thienyl rings and CF3 groups which is present here and in similar compounds.

A Novel Electrophilic Diamination Reaction of Alkenes.

A three-component electrophilic reaction transforms olefins into imidazoline and diamine derivatives. Rhodium(II) heptafluorobutyrate dimer (2 mol %) was utilized as the catalyst and N,N-dichloro-p-toluenesulfonamide (TsNCl ) and acetonitrile as the nitrogen sources. Modest to good yields (45-82 %) and high regio- and stereoselectivity were achieved.

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.

Purpose: Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that are believed to be involved in primary and metastatic tumor growth by degrading the basement membrane and changing the extracellular matrix to facilitate invasion of malignant cells and angiogenesis. Overexpression of MMPs has been documented in various solid tumors. BAY12-9566 is a selective inhibitor of MMPs, in particular MMP-2, -3.

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 x 10(11) and 1 x 10(13) viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Purpose: Sodium phenylbutyrate (PB) demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. We conducted a Phase I and pharmacokinetic study of PB by continuous infusion to characterize the maximum tolerated dose, toxicities, pharmacokinetics, and antitumor effects in patients with refractory solid tumors.

Patients And Methods: Patients were treated with a 120-h PB infusion every 21 days.

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

Purpose: Phenylbutyrate (PB) is an aromatic fatty acid with multiple mechanisms of action including histone deacetylase inhibition. Preclinically, PB demonstrates both cytotoxic and differentiating effects at a concentration of 0.5 mM.

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.

Objectives: To develop a model that will identify a contemporary cohort of patients at high risk of early prostate cancer recurrence (greater than 50% at 36 months) after radical retropubic prostatectomy for clinically localized disease. Data from this model will provide important information for patient selection and the design of prospective randomized trials of adjuvant therapies.

Methods: Proportional hazards regression analysis was applied to two patient cohorts to develop and cross-validate a multifactorial predictive model to identify men with the highest risk of early prostate cancer recurrence.

Lanthanide coordination with alpha-amino acids under near physiological pH conditions: polymetallic complexes containing the cubane-like [Ln4(mu3-OH)4]8+ cluster core.

Tetranuclear lanthanide-hydroxo complexes of the general formula [Ln(4)(mu(3)-OH)(4)(AA)(x)(H(2)O)(y)](8+) (1, Ln = Sm, AA = Gly, x = 5, y = 11; 2, Ln = Nd, AA = Ala, x = 6, y = 10; 3, Ln = Er, AA = Val, x = 5, y = 10) have been prepared by alpha-amino acid controlled hydrolysis of lanthanide ions under near physiological pH conditions (pH 6-7). The core component of these compounds is a cationic cluster [Ln(4)(mu(3)-OH)(4)](8+) whose constituent lanthanide ions and triply bridging hydroxo groups occupy the alternate vertexes of a distorted cube. The amino acid ligands coordinate the lanthanide ions via bridging carboxylate groups.

Prostate cancer prevention strategies using antiproliferative or differentiating agents.

Differentiation or antiproliferative therapies have been most effective in the treatment of promyelocytic leukemia and are being investigated for the treatment of solid tumors including prostate cancer (PCa). Research suggests that these agents may induce terminal differentiation (arrest in G(0)), induce differentiation to a mature cell with cellular functions and a growth pattern similar to nonmalignant cells, or trigger apoptosis. This review focuses on classes of agents under laboratory and clinical evaluation as antiproliferative or differentiating agents: polyamine inhibitors, vitamin D and its analogs, metabolites of vitamin A, the short-chain fatty acid, phenylbutyrate, and nonsteroidal anti-inflammatory agents.

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

Differentiation-inducing agents, such as retinoids and short-chain fatty acids, have an inhibitory effect on tumor cell proliferation and tumor growth in preclinical studies. Clinical trials involving these compounds as single agents have been suboptimal in terms of clinical benefit. Our study evaluated the combination of phenylbutyrate (PB) and 13-cis retinoic acid (CRA) as a differentiation and antiangiogenesis strategy for prostate cancer.

Analogues for the molybdenum center of sulfite oxidase: oxomolybdenum(V) complexes with three thiolate sulfur donor atoms.

cis,trans-(L-N2S2)Mo(V)O(SR) [L-N2S2H2 = N,N'-dimethyl-N,N'-bis(mercaptophenyl)ethylenediamine; R = CH2Ph, CH2CH3, and p-C6H4-Y (Y = CF3, Cl, Br, F, H, CH3, CH2CH3, and OCH3)] are the first structurally characterized mononuclear Mo compounds with three thiolate donors, as occurs at the Mo active site in sulfite oxidase. X-ray crystal structures of the cis,trans-(L-N2S2)Mo(V)O(SR) compounds, where R = CH2Ph, CH2CH3, p-C6H4-OCH3, and p-C6H4-CF3, show a similar coordination geometry about the Mo atom with all three sulfur thiolate donors in the equatorial plane. This coordination geometry places two adjacent S ppi orbitals parallel to the Mo=O bond, analogous to the orientation in the ene-dithiolate ligand in sulfite oxidase; the third S ppi orbital lies in the equatorial plane.

Electronic spectral studies of molybdenyl complexes. 2. MCD spectroscopy of [MoOS4]- centers.

Magnetic circular dichroism (MCD) and absorption spectroscopies have been used to probe the electronic structure of [PPh4][MoO(p-SC6H4X)4] (X = H, Cl, OMe) and [PPh4][MoO(edt)2] complexes (edt = ethane-1,2-dithiolate). The results of density functional calculations (DFT) on [MoO(SMe)4]- and [MoO(edt)2]- model complexes were used to provide a framework for the interpretation of the spectra. Our analysis shows that the lowest energy transitions in [MoVOS4] chromophores (S4 = sulfur donor ligand) result from S-->Mo charge transfer transitions from S valence orbitals that lie close to the ligand field manifold.

Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.

We report 5 patients with advanced metastatic prostate cancer who took bicalutamide 50 mg/day for "second-line" hormonal manipulation and demonstrated a rapid rise in prostate-specific antigen (PSA) shortly after the initiation of bicalutamide. After discontinuation of the drug, PSA levels declined in 4 patients and stabilized in the fifth. In 2 of the patients, the PSA rise was associated with an increase in pain level, which subsided after the treatment was stopped.

Dendron-Controlled Nucleation and Growth of Gold Nanoparticles.

Passivation of the metal surface by dendrons bearing a focal 4-pyridone functionality (the second-generation dendron is shown; C: gray, N: blue, O: red) allows controlled nucleation and growth of gold nanoclusters. The particle size is a direct function of the generation number of the dendritic ligands, with higher generation dendron producing larger particles.

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.

Compounds that inhibit histone deacetylase may enable the re-expression of silenced regulatory genes in neoplastic cells, reversing the malignant phenotype. Although several molecules that inhibit histone deacetylase are undergoing preclinical development, butyric acid derivatives have undergone clinical investigation for several years, initially for non-malignant indications and more recently for the treatment of cancer. Of the butyric acid derivatives, sodium phenylbutyrate has undergone the most extensive systematic investigation.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

When irradiated and administered intradermally as vaccines, cancer cells engineered to secrete high levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) by gene transfer elicit potent anticancer immune responses in a variety of animal tumor models. Upon vaccination, antigens present in the cancer cells are phagocytosed and processed by skin dendritic cells. These dendritic cells then prime anticancer immune responses by presenting antigenic peptides to T cells.